Some aspects of the endocrine profile and management of hormone-dependent male breast cancer.
The management of hormone-dependent male breast cancer is insufficiently understood by practicing oncologists. This article provides a review of the endocrine profile of male breast cancer, and outlines the differences between hormone-dependent female and male breast cancers. A concise review of the past, present, and possible future management of hormone-dependent male breast cancer is presented. For a better understanding of this disease, more information on the natural history and biological behaviors of patients with male breast cancer is needed. This could be accomplished by the development of a specific multi-institutional tumor registry and execution of prospective clinical trials.
Michigan State University, B413 Clinical Center, East Lansing, MI 48824, USA. dimitrov@msu.edu
Nikolay V
NV
Dimitrov
Philomena
P
Colucci
Sunil
S
Nagpal
D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology / Q000627:therapeutic use; D018567:Breast Neoplasms, Male / Q000188:drug therapy / Q000378:metabolism*; D004702:Endocrine Glands / Q000187:drug effects / Q000378:metabolism; D004967:Estrogens / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000502:physiology / Q000627:therapeutic use; D020845:Selective Estrogen Receptor Modulators / Q000494:pharmacology / Q000627:therapeutic use; D013629:Tamoxifen / Q000494:pharmacology / Q000627:therapeutic use; D013739:Testosterone / Q000378:metabolism*
D018931:Antineoplastic Agents, Hormonal; D004967:Estrogens; D011960:Receptors, Estrogen; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; D013739:Testosterone